fashion -WSS

fashion

author：entertainment 2025-08-28 13:04:28 - browse：7785

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Severe heat forecast: Where scorching temperatures will persist over the next week

knowledge

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Gene therapy for Afghan refugees’ infant will be fully covered

A single Democrat is willing to weaken Medicare negotiation power

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Medicare Advantage plans can’t deny care with AI, CMS warns

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Cano Health’s bankruptcy is a warning for Medicare Advantage

Anesthesiologist group: stop taking Ozempic before surgery

What Henrietta Lacks's story taught me about my role as a doctor

Supreme Court strikes down use of affirmative action

What’s missing from the debate over nursing home staff minimums

Bright Health sells Medicare Advantage business to Molina

Updated Covid vaccine has 54% effectiveness, new study suggests

Apple is now the first public company to be valued at $3 trillion

Thousands protest mob assault of women who were paraded naked in remote Indian border state

focus

Burning questions about Delta and the next phase of the Covid pandemic

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Bernie brings in new pharma CEOs to talk drug prices

Padmanee Sharma of MD Anderson at center of lawsuit over credit

How to protect coverage of PrEP

Problems with a popular proposal to regulate AI in health care

entertainment

knowledge

focus

entertainment